Pablo Catarecha, Ma Dolores Segura, José M. Franco‐Zorrilla, Berenice García‐Ponce, Mónica Lanza, Roberto Solano, Javier Paz‐Ares, Antonio Leyva,
The exceptional toxicity of arsenate [As(V)] is derived from its close chemical similarity to phosphate (Pi), which allows the metalloid to be easily incorporated into plant cells through the high-affinity Pi transport system. In this study, we identified an As(V)-tolerant mutant of Arabidopsis thaliana named pht1;1-3, which harbors a semidominant allele coding for the high-affinity Pi transporter PHT1;1. pht1;1-3 displays a slow rate of As(V) uptake that ultimately enables the mutant to accumulate ...
Tópico(s): Plant nutrient uptake and metabolism
2007 - Oxford University Press | The Plant Cell
Berenice García‐Ponce, José M. Franco‐Zorrilla, Vicente Rubio, Preeti Dahiya, Javier Paz‐Ares, Antonio Leyva,
Summary The differentiation of vascular tissue plays a central role in root architecture and its functionality. Regardless of its importance, the molecular mechanisms involved in the inception of vascular morphogenesis and their interaction with hormones are only now beginning to be understood. The characterisation of the WOODEN LEG ( wol/cre1 mutant), impaired in procambial cell proliferation and the identification of WOL/CRE1 as a cytokinin receptor, provided the first genetic evidence pointing ...
Tópico(s): Plant Reproductive Biology
2004 - Wiley | The Plant Journal
M. Teresa Agulló-Ortuño, Inmaculada García‐Ruíz, C. Vanesa Díaz-García, Ana B. Enguita, Virginia Pardo, Elena Prieto‐García, Santiago Ponce, L. Iglesias, Jon Zugazagoitia, José A. López-Martín, Luis Paz‐Ares, Juan Antonio Vargas,
Tópico(s): Ferroptosis and cancer prognosis
2019 - Springer Science+Business Media | Cancer Chemotherapy and Pharmacology
Jon Zugazagoitia, Asunción Díaz, Elisabeth Jiménez, Juan Antonio Vargas, L. Iglesias, Santiago Ponce-Aix, Luis Paz‐Ares,
Dacomitinib is a second-generation, irreversible, covalent pan-HER tyrosine-kinase inhibitor (TKI). It showed potent EGFR signaling inhibition in experimental models, including first-generation TKI resistant NSCLC cell-lines. This preclinical efficacy did not translate into clinically meaningful treatment benefits for advanced, pretreated, molecularly unselected non-small-cell lung cancer (NSCLC) patients enrolled in 2 parallel phase III trials. Dacomitinib and erlotinib showed overlapping efficacy ...
Tópico(s): Gastric Cancer Management and Outcomes
2017 - Frontiers Media | Frontiers in Medicine
Daniel P. Chin, Kathryn DeRiemer, Peter M. Small, Alfredo Ponce‐de‐León, Rachel Steinhart, Gisela Schecter, Charles L. Daley, Andrew R. Moss, E. ANTONIO PAZ, Robert M. Jasmer, C B Agasino, Philip C. Hopewell,
To determine the factors contributing to tuberculosis incidence in the U.S.-born and foreign-born populations in San Francisco, California, and to assess the effectiveness of tuberculosis control efforts in these populations, we performed a population-based molecular epidemiologic study using 367 patients with strains of Mycobacterium tuberculosis recently introduced into the city. IS6110-based and PGRS-based restriction fragment length polymorphism (RFLP) analyses were performed on M. tuberculosis ...
Tópico(s): Infectious Diseases and Tuberculosis
1998 - American Thoracic Society | American Journal of Respiratory and Critical Care Medicine
Mónica Lanza, Berenice García‐Ponce, Gabriel Castrillo, Pablo Catarecha, Michael Sauer, María Rodríguez‐Serrano, Ana Páez-García, Eduardo Sánchez-Bermejo, Mohan TC, Yolanda Leo del Puerto, Luisa M. Sandalio, Javier Paz‐Ares, Antonio Leyva,
In plants, developmental programs and tropisms are modulated by the phytohormone auxin. Auxin reconfigures the actin cytoskeleton, which controls polar localization of auxin transporters such as PIN2 and thus determines cell-type-specific responses. In conjunction with a second growth-promoting phytohormone, brassinosteroid (BR), auxin synergistically enhances growth and gene transcription. We show that BR alters actin configuration and PIN2 localization in a manner similar to that of auxin. We describe ...
Tópico(s): Plant nutrient uptake and metabolism
2012 - Elsevier BV | Developmental Cell
Jon Zugazagoitia, Daniel Rueda, Nuria Carrizo, Ana B. Enguita, David Gómez-Sánchez, Asunción Díaz-Serrano, Elisabeth Jiménez, Antonio Mérida, Rosa Calero, Ricardo García Luján, Eduardo de Miguel, Pablo Gámez, V. Díaz-Hellín, Juan Antonio Vargas, L. Iglesias, Irene Ferrer, Luis Paz‐Ares, Santiago Ponce-Aix,
Introduction A substantial fraction of non–small-cell lung cancers (NSCLCs) harbor targetable genetic alterations. In this study, we analyzed the feasibility and clinical utility of integrating a next-generation sequencing (NGS) panel into our routine lung cancer molecular subtyping algorithm. Patients and Methods After routine pathologic and molecular subtyping, we implemented an amplicon-based gene panel for DNA analysis covering mutational hot spots in 22 cancer genes in consecutive advanced-stage ...
Tópico(s): RNA modifications and cancer
2017 - Elsevier BV | Clinical Lung Cancer
Juan Antonio Paz-González, Carlos Velasco‐Santos, Luis Jesús Villarreal-Gómez, Enrique Alcudia-Zacarías, A. Olivas, M. Cota–Leal, Lucı́a Z. Flores-López, Yadira Gochi‐Ponce,
In recent years, surgical procedures for hip prostheses have increased. These implants are manufactured with materials with high stiffness compared to the bone, causing bone loss or aseptic loosening. This research proposes an alternative structural composite consisting of 3D-printing polylactic acid layers and carbon fiber laminates (PLA/CFRC) with potential application in prosthetic implants. Fourier-transform infrared spectroscopy (FTIR) achieved to characterize starting materials and structural ...
Tópico(s): Orthopaedic implants and arthroplasty
2022 - Elsevier BV | Journal of the mechanical behavior of biomedical materials/Journal of mechanical behavior of biomedical materials
Vivek Subbiah, Luis Paz‐Ares, Benjamin Besse, Víctor Moreno, Solange Peters, María Ángeles Sala, José Antonio López-Vilariño, Cristian Fernández, Carmen Kahatt, Vicente Alfaro, Mariano Siguero, Ali Zeaiter, Khalil Zaman, Rafael López‐López, Santiago Ponce, Valentina Boni, Jennifer Arrondeau, Jean‐Pierre Delord, Maite Martínez, Luciano Wannesson, Antonio Antón, Javier Valdivia, Ahmad Awada, Rebecca Kristeleit, M.E. Olmedo, María Jesús Rubio, John Sarantopoulos, Sant P. Chawla, Joaquín Mosquera, Manolo D’ Arcangelo, Armando Santoro, Víctor M. Villalobos, Jacob Sands, José Trigo,
The National Comprehensive Cancer Network guidelines recommend re-challenge with the first-line treatment for relapsed small cell lung cancer (SCLC) with chemotherapy-free interval (CTFI)≥180 days. A phase II study (NCT02454972) showed remarkable antitumor activity in SCLC patients treated with lurbinectedin 3.2 mg/m2 1 -h intravenous infusion every 3 weeks as second-line therapy. We report results for the pre-planned subset of patients with CTFI ≥ 180 days.Twenty patients aged ≥18 years with pathologically ...
Tópico(s): Peptidase Inhibition and Analysis
2020 - Elsevier BV | Lung Cancer
Santiago Ponce-Aix, Gregory M. Coté, Alejandro Falcón, E. Jimenez-Aguilar, W. Marston Linehan, Ioan Şimon, M.J. Flor, Ramiro Manzano-Núñez, Antonio Moreno Jiménez, Elisabeth Jiménez, S. Extremera, Carmen Kahatt, Ali Zeaiter, Luis Paz‐Ares,
Lurbinectedin is a novel anti-cancer agent that exerts antitumor activity through inhibition of trans-activated transcription and modulation of the tumor microenvironment. In June 2020, the US FDA granted accelerated approval to lurbinectedin (ZepzelcaTM) for the treatment of adult patients (pts) with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy based on the results of a phase II study (Trigo et al. Lancet Oncol 2020). Preclinical evidence ...
Tópico(s): Lung Cancer Treatments and Mutations
2021 - Elsevier BV | Journal of Thoracic Oncology
Antonio Arroyo-Paz, Yalmar Ponce Atencio,
Water is a fundamental resource, eutrophication is an important factor in determining water quality, and chlorophyll-a is an indicator of this degree. Artificial intelligence offers important tools to help improve classification and prediction for inland water studies such as lakes. This study evaluated the water quality in the Lake Titicaca basin (Peruvian sector), using the monitoring results of the Instituto del Mar del Perú (IMARPE), between 2011 and 2021. The dataset used in the study included ...
Tópico(s): Hydrological Forecasting Using AI
2023 - Springer Science+Business Media | Communications in computer and information science
Anayanci Mendoza Villicana, Yadira Gochi‐Ponce, Daniel Grande, José Manuel Cornejo‐Bravo, Arturo Zizumbo‐López, Marlon César González Joaquín, Rocío Alejandra Chávez-Santoscoy, Juan Antonio Paz-González, Nina Bogdanchikova, Graciela Lizeth Pérez-González, Luis Jesús Villarreal-Gómez,
Currently, wound dressing technology is of significant interest in order to avoid undesired effects when burns or skin wounds are treated, especially their risk for microbial contamination and subsequent infection. Silver nanoparticles (AgNPs) have claimed importance as antimicrobial agents. For these reasons, a comparative study of different methods to synthesize electrospun polymeric fibers loaded with AgNPs (Ag+/PCLPVP) such as direct blending, ultraviolet irradiation, thermal treatment, and silver ...
Tópico(s): Nanoparticles: synthesis and applications
2023 - Taylor & Francis | Polymer-Plastics Technology and Materials
Juan Antonio Paz-González, Yadira Gochi‐Ponce, Carlos Velasco‐Santos, Enrique Alcudia-Zacarías, Arturo Zizumbo‐López, Balter Trujillo-Navarrete, Oscar Adrián Morales Contreras, Luis Jesús Villarreal-Gómez,
Tópico(s): Additive Manufacturing and 3D Printing Technologies
2025 - Multidisciplinary Digital Publishing Institute | Journal of Composites Science
Alejandro Navarro, Santiago Ponce Aix, I.C. Barneto Aranda, Egbert F. Smit, José Antonio López-Vilariño, Antonio Martínez Nieto, Carmen Kahatt, Ali Zeaiter, Sophie Cousin, Helge Bischoff, Jaromı́r Roubec, Konstantinos Syrigos, Luis Paz‐Ares,
8524 Background: Lurbinectedin, a selective inhibitor of oncogenic transcription, received accelerated approval from the US FDA in June 2020 as monotherapy (3.2 mg/m 2 IV every 21 days) for adults with metastatic SCLC with disease progression on or after platinum-based chemotherapy. This approval was based on the overall response rate (35.2%) and duration of response (DOR; 5.3 months) observed in 105 patients from a phase 2 trial. The ATLANTIS trial (NCT02566993) investigated the combination of lurbinectedin ...
Tópico(s): Pancreatic and Hepatic Oncology Research
2022 - Lippincott Williams & Wilkins | Journal of Clinical Oncology
M. Teresa Agulló-Ortuño, Cecilia Diaz-Garcia, José A. López-Martín, Elena Prieto‐García, Santiago Ponce, Jon Zugazagoitia, Lara Iglesias-Docampo, Ana B. Enguita, Luis Paz‐Ares, Juan Antonio Núñez-Sobrino,
Abstract BACKGROUND: Pemetrexed is an effective antineoplastic agent as monotherapy (second line and maintenance setting) or in platinum-based combination regimes (first-line). Pemetrexed inhibits three key enzymes in the folate metabolic pathway: thymidylate synthase (TS), dihydrofolate reductase (DHFR) and glycinamide ribonucleotide formyl transferase (GARFT). As a consequence, pemetrexed interferes with the synthesis of both pyrimidine and purine, thereby effectively inhibiting both DNA and RNA synthesis. ...
Tópico(s): Colorectal Cancer Treatments and Studies
2016 - American Association for Cancer Research | Cancer Research
Gonzalo Peraza‐Mues, Roberto Ponce-López, Juan Antonio Muñoz Sanchez, F Alanís, Grissel Olivera Martínez, Carlos Brambila Paz,
Since the 1950s, researchers in Urban Geography have created multiple instruments for measuring income segregation. However, the computation of such indexes requires the availability of income data and population distribution for small areal units. This approach is problematic for countries and cities where a government's decennial census does not collect or report income data for small‐enough areal units to capture income variability within a neighborhood. To address this gap, we use Iterative ...
Tópico(s): demographic modeling and climate adaptation
2023 - Wiley | Geographical Analysis
Santiago Ponce, Emiliano Calvo, Maria J. de Miguel, C. Sessa, M.J. Flor, A. Drilon, Alejandro Falcón, Ioan Şimon, Ramiro Manzano-Núñez, Xarles Erik Luepke, N. Cuevas-Melendez, José Antonio López-Vilariño, Salvador Fudio, Mariano Siguero, Martín Cullell-Young, Carmen Kahatt, Ali Zeaiter, Luis Paz‐Ares,
L is a new agent that exerts antitumor activity through inhibition of trans-activated transcription and modulation of tumor microenvironment. Preclinical evidence of synergism was observed for L in combination with P and I. Activity of combinations with LP and LI in small cell lung cancer (SCLC) was reviewed in two phase Ib trials. Patients were enrolled following a 3+3 dose escalation design. SCLC patients with ECOG performance status (PS) 0-1 and pretreated with at least one platinum-based chemotherapy ...
Tópico(s): Glycosylation and Glycoproteins Research
2019 - Elsevier BV | Journal of Thoracic Oncology
A. Modrego, Helena Bote, E. Jimenez-Aguilar, Santiago Ponce-Aix, Jon Zugazagoitia, José Manuel Baena, José M. Mazarico, Juan Antonio Vargas, L. Iglesias, Luis Paz‐Ares,
Atezolizumab and nivolumab are approved in patients with advanced previously treated non-small cell lung cancers (NSCLC) irrespective of programmed death-ligand 1 (PD-L1) expression, while pembrolizumab is only approved if PD-L1 ≥1%. At present, immunotherapy alone or in combination with chemotherapy is the treatment of choice for first-line NSCLC, however treatment with anti-PD-1/PD-L1 agents should be reconsidered after progression to chemotherapy in patients which did not receive immunotherapy at ...
Tópico(s): Pancreatic and Hepatic Oncology Research
2021 - Elsevier BV | Journal of Thoracic Oncology
Helena Bote, A. Modrego, E. Jimenez-Aguilar, José M. Mazarico, Juan Antonio Núñez-Sobrino, L. Iglesias, José Manuel Baena, Jon Zugazagoitia, Santiago Ponce-Aix, Luis Paz‐Ares,
Stage III non-small cell lung cancer (NSCLC) is a heterogeneous disease which includes patients with different prognosis depending on resectable, potentially resectable or unresectable tumours. Chemo-immunotherapy in neoadjuvant setting is currently under evaluation in clinical trials. We present two case reports of patients who received this therapeutic approach due to tumour unresectability at diagnosis.
Tópico(s): Lung Cancer Research Studies
2021 - Elsevier BV | Journal of Thoracic Oncology
María Vieito, Santiago Ponce Aix, Luis Paz‐Ares, Rastilav Bahleda, Christophe Massard, Leyre Agreda, Eva Banus, Cristian Marcelo Fernandez, Elena Y Cristoveanu, Gema Corral, Lourdes Llanero, Rubin Lubomirov, Carmen Kahatt, Salvador Fudio, Antonio Nieto, Martín Cullell-Young, Ali Zeaiter, H.K. Oberoi, Elena Garralda,
3078 Background: PM14 is a new chemical entity that forms DNA adducts which specifically inhibit RNA synthesis and block active transcription of protein-coding genes. Antitumor activity has been demonstrated in vitro in several cell lines (e.g. lung, kidney, prostate), and in vivo in mice bearing xenografted human-derived tumors (soft tissue sarcoma, small cell lung cancer, ovarian, gastric, breast and renal cancer). Methods: Open-label, dose-escalating, phase I trial of PM14 administered as a 3-hour ...
Tópico(s): Cancer Research and Treatments
2021 - Lippincott Williams & Wilkins | Journal of Clinical Oncology
Jon Zugazagoitia, A. Falcon Gonzalez, A.F. Navarro Mendivil, Amparo Sánchez-Gastaldo, P.F. Simoes da Rocha, Gregory M. Coté, B. Bockorny, J. Molina Cerrillo, A. Artal, J. Baena Espinar, A. Gil Torralvo, Santiago Ponce Aix, Helena Bote de Cabo, J. Martínez Pérez, Sagrario Martínez Cortijo, José Antonio López-Vilariño, Carmen Kahatt, Javier Gómez, Luis Paz‐Ares,
Tópico(s): Lung Cancer Treatments and Mutations
2024 - Elsevier BV | Annals of Oncology
Luis Paz‐Ares, Alejandro Falcón, Alejandro Navarro, Amparo Sánchez-Gastaldo, Gregory M. Coté, Bruno Bockorny, Javier Molina‐Cerrillo, Á. Artal, Javier Baena Preysler, Ana Gil, Santiago Ponce Aix, Helena Bote de Cabo, Sara Martínez, J. Martínez, José Antonio López-Vilariño, Carmen Kahatt, Ali Zeaiter, Javier Gómez, Jon Zugazagoitia,
8094 Background: LUR has been approved in the US and elsewhere for treatment of adult pts with metastatic SCLC and disease progression on or after platinum-based chemotherapy. Preclinical studies found synergy for LUR with IRI (Galmarini C. Cancer Res 2013; 73: Abst 5499). The phase 1b/2 study PM1183-A-014-15 (NCT02611024) evaluated the LUR/IRI combination in pretreated pts with advanced solid tumors. The phase 1b part defined the recommended dose at LUR 2.0 mg/m 2 on Day (D)1 + IRI 75 mg/m 2 on D1,D8 ...
Tópico(s): Pneumonia and Respiratory Infections
2024 - Lippincott Williams & Wilkins | Journal of Clinical Oncology
Carl D. Schlichting, Massimo Pigliucci,
... Mega, Alma Piñeyro-Nelson, Crisanto Gutierrez, Berenice García-Ponce, María De La Paz Sánchez, Estephania Zluhan-Martínez, Elena R. Álvarez-Buylla, ...
Tópico(s): Plant Reproductive Biology
1993 - University of Chicago Press | The American Naturalist
Santiago Ponce Aix, Jon Zugazagoitia, Pilar González‐Márquez, Maria Angeles Torres Nieto, Joan M. Gasent Blesa, Xabier Mielgo-Rubio, Carmen Paz, Rosa Quiben, Juan Luis García Llano, Carmen Perez Agua, Pilar Resano, Julia Calzas, Lourdes García, Victor M. Diaz Muñoz, L. Iglesias, Juan Antonio Vargas, Rosa María García Martín, H. Cortés-Funes, José Luis Rodríguez‐Peralto, Ana Belén Enguita Valls,
e22112 Background: Detection of EGFR m in p with NSCLC is done in a routine way. Given the data published on ALK positive p detection is crucial for therapeutic decision making. ALK t should be performed using FISH break apart probes for selecting p but probably is not enough quick for clinical wide use. Based on promising results IHC assay may be used as screening. We implemented a systematic determination of EGFR m and ALK t status to asses feasibility and accuracy in a clinical setting. Methods: ...
Tópico(s): Lung Cancer Research Studies
2014 - Lippincott Williams & Wilkins | Journal of Clinical Oncology
Vivek Subbiah, Luis Paz‐Ares, Benjamin Besse, Víctor Moreno, Khalil Zaman, M.Á. Sala González, José Antonio López-Vilariño, Cristian Marcelo Fernandez, Carmen Kahatt, Mariano Siguero, Ali Zeaiter, Rafael López‐López, Santiago Ponce Aix, V. Boni, Jennifer Arrondeau, J.P. Delord, Maite Martínez-Aguillo, L. Wannesson De Nicola, A. Antón Torres, J.M. Trigo Perez,
Remarkable activity was observed with lurbinectedin in patients (pts) with relapsed small-cell lung cancer (SCLC) in a phase II Basket trial (Trigo et al. 2020). NCCN guidelines recommend platinum re-challenge if chemotherapy-free interval (CTFI) >180 days (d) based on small clinical trials mostly conducted in the 1980s. Recent data on re-challenge with CTFI >90 d showed overall response rate (ORR) of 45-49% and median overall survival (OS) of 7.5-7.9 months (mo) (Genestreti et al. 2015; Monnet et al. 2019). ...
Tópico(s): Peptidase Inhibition and Analysis
2020 - Elsevier BV | Annals of Oncology
Francisco J. Lara, Hiroma Tamaki, C. Pavan,
... org/10.1016/0045-6039(75)90028-7Benjamin Paz Aliaga, Manuel Troyano Pueyo, Percy Noriega Ponce, F.J.S. Lara Isolation and characterization of ...
Tópico(s): Insect behavior and control techniques
1965 - University of Chicago Press | The American Naturalist
José Trigo, Vivek Subbiah, Benjamin Besse, Víctor Moreno, Rafael López‐López, María Ángeles Sala, Solange Peters, Santiago Ponce, Cristian Fernández, Vicente Alfaro, Javier Gómez, Carmen Kahatt, Ali Zeaiter, Khalil Zaman, Valentina Boni, Jennifer Arrondeau, Maite Martínez, Jean‐Pierre Delord, Ahmad Awada, Rebecca Kristeleit, M.E. Olmedo, Luciano Wannesson, Javier Valdivia, María Jesús Rubio, Antonio Antón, John Sarantopoulos, Sant P. Chawla, Joaquín Mosquera, M. D’Arcangelo, Armando Santoro, Víctor M. Villalobos, Jacob Sands, Luis Paz‐Ares,
Background Few options exist for treatment of patients with small-cell lung cancer (SCLC) after failure of first-line therapy. Lurbinectedin is a selective inhibitor of oncogenic transcription. In this phase 2 study, we evaluated the acti and safety of lurbinectedin in patients with SCLC after failure of platinum-based chemotherapy. Methods In this single-arm, open-label, phase 2 basket trial, we recruited patients from 26 hospitals in six European countries and the USA. Adults (aged ≥18 years) with ...
Tópico(s): Cancer therapeutics and mechanisms
2020 - Elsevier BV | The Lancet Oncology
Josef Thaler, Richard Greil, Johannes Gaenzer, Wolfgang Eisterer, Jörg Tschmelitsch, Hellmut Samonigg, August Zabernigg, Franz X. Schmid, Günther Steger, Robert Steinacher, Johannes Andel, Alois Lang, R. Függer, F Hofbauer, Ewald Woell, D. Geißler, A. Lenauer, Manfred Prager, Jean–Luc Van Laethem, Eric Van Cutsem, Geert R. D’Haens, Gauthier Demolin, Joseph Kerger, Guido Deboever, G. Ghillebert, Marc Polus, Eric Van Cutsem, Hassan RezaieKalantari, Thierry Delaunoit, Jean Charles. Goeminne, Marc Peeters, Philippe Vergauwe, Ghislain Houbiers, Yves Humblet, Jos Janssens, Dirk Schrijvers, Erik Vanderstraeten, Jean–Luc Van Laethem, Jan B. Vermorken, Daniel Van Daele, Michel Ferrante, Frédéric Forget, Alain Hendlisz, Mette Yilmaz, Svend Erik Nielsen, Lene Weber Vestermark, J LARSEN, Marc Ychou, Ayman Zawadi, Mohamed-Ayman Zawadi, Olivier Bouché, Laurent Mineur, Jaafar Bennouna-Louridi, Louis Marie Dourthe, Marc Ychou, Éveline Boucher, Julien Taı̈eb, Denis Pezet, Françoise Desseigne, Michel Ducreux, Patrick Texereau, Laurent Miglianico, Philippe Rougier, Serge Fratté, Charles-Briac Levaché, Yacine Merrouche, Stephen G. Ellis, Christophe Locher, Jean‐François Ramée, Claire Garnier, F. Viret, Bruno Chauffert, Isabelle Cojean-Zelek, Pierre Michel, Cédric Lecaille, Christian Borel, Jean‐François Seitz, Denis Smith, Catherine Lombard‐Bohas, Thierry André, Jean‐Marc Gornet, Francine Fein, Marie-Aude Coulon-Sfairi, Marie‐Christine Kaminsky, Jean-Paul Lagasse, Dominique Luet, Pierre-Luc Etienne, Mohamed Gasmi, André Vanoli, Suzanne Nguyen, Thomas Aparicio, H. Perrier, Noël Stremsdoerfer, Philippe Laplaige, Dominique Arsène, Dominique Auby, Laurent Bedenne, Romain Coriat, Bernard Denis, Pierre A. Geoffroy, G. Piot, Y. Bécouarn, Gilbert Bordes, G. Deplanque, Olivier Dupuis, F. Fruge, Rosine Guimbaud, Thierry Lecomte, Gérard Lledo, I. Sobhani, Amani Asnacios, A. Azzedine, Christophe Desauw, Marie‐Pierre Galais, D. Gargot, You-Heng Lam, Abakar Abakar-Mahamat, Jean-François Berdah, Sylviane Catteau, Marie-Christine Clavero-Fabri, Jean-François Codoul, Jean-Louis Legoux, D Goldfain, Pierre Guichard, Denis Père Verge, Jocelyne Provençal, B. Védrenne, Catherine Brezault‐Bonnet, D Cléau, Jean-Paul Desir, David Fallik, Bruno García, M Gaspard, Dominique Genet, Johannes Hartwig, Yves Krummel, Tamara MatysiakBudnik, Vanessa Palascak-Juif, Harizo Randrianarivelo, Yves Rinaldi, Albert Aleba, Ariane Darut‐Jouve, Aimery de Gramont, Hervé Hamon, Frédéric Wendehenne, Axel Matzdorff, M. Stahl, Wolfgang Schepp, M. Burk, Lothar Mueller, Gunnar Folprecht, Michael Geißler, Luisa Mantovani-Loeffler, Thomas Hoehler, Walter Asperger, Hendrik Kroening, Ludwig Fischer von Weikersthal, Stefan Fuxius, Matthias Groschek, Jens Meiler, Tanja Trarbach, Jacqueline Rauh, Nicolas Ziegenhagen, Albrecht Kretzschmar, Ullrich Graeven, Arnd Nusch, Goetz von Wichert, Ralf‐Dieter Hofheinz, G. Kleber, Karl‐Heinz Schmidt, Ursula Vehling‐Kaiser, Claudia Baum, Jochen Schuette, Georg Martin Haag, W. Holtkamp, Jochen Potenberg, T Reiber, Georg Schliesser, Hans‐Joachim Schmoll, Wolfgang Schneider-Kappus, Wolfgang Abenhardt, Claudio Denzlinger, Jan Henning, Bartscht Marxsen, Hans GuenterDerigs, Helmut Lambertz, Ingulf Becker-Boost, Karel Caca, Carolina Constantin, Thomas Decker, H. Eschenburg, Sigrun Gabius, Holger Hebart, Albrecht Hoffmeister, Heinz‐August Horst, Stephan Kremers, Malte Leithaeuser, Sebastian Mueller, Siegfried Wagner, S Daum, Frank Schlegel, Martina Stauch, Volker Heinemann, Roberto Labianca, Giuseppe Colucci, Dino Amadori, Enrico Mini, Alfredo Falcone, C. Boni, Evaristo Maiello, Luciano Latini, Alberto Zaniboni, Dino Amadori, Giuseppe Aprile, Sandro Barni, Rodolfo Mattioli, Andrea Martoni, Rodolfo Passalacqua, Mario Nicolini, E. Pasquini, Carla Rabbi, Enrico Aitini, Alberto Ravaioli, Carlo Barone, Guido Biasco, Stefano Tamberi, Angelo Gambi, Claudio Verusio, Marina Marzola, G. Lelli, C. Boni, Stefano Cascinu, Paolo Bidoli, Massimo Vaghi, Giorgio Cruciani, Francesco Di Costanzo, Alberto Sobrero, Enrico Mini, Roberto Petrioli, Massimo Aglietta, Oscar Alabiso, Federico Capuzzo, Alfredo Falcone, D.C. Corsi, Roberto Labianca, Stefania Salvagni, Silvana Chiara, Francesco Ferraù, Francesco Giuliani, Sara Lonardi, Nicola Gebbia, Giovanni Mantovani, Evaristo Sanches, Evaristo Sanches, Juan Carlos Mellidez, Pedro Santos, J. Costa Freire, Cristina Montalvão Sarmento, Luís Henrique M. K. Costa, Antonio Pinto, Sérgio Barroso, Jorge Espírito Santo, Fátima Guedes, Amelia Yuting Monteiro, Anabela Sá, Irene Furtado, Josep Tabernero, Ramón Salazar, Enrique Aranda, F. Rivera Herrero, Josep Tabernero, Javier Sastre Valera, Manuel ValladaresAyerbes, Jaime FeliuBatlle, Silvia Gil, Carlos García Girón, Guillermo López-Vivanco, Antonia Salud Salvia, Vicente Alonso Orduña, Ruth Vera García, Javier Gállego, B. Massuti Sureda, Jordi Remón, M.J. Safont Aguilera, Luis Cirera-Nogueras, BernadoQueralt Merino, Cristina Grávalos Castro, Purificación Martínez de Prado, Carlos PijaumePericay, Manuel ConstenlaFigueiras, InmaculadaGuasch Jordan, Maria Jose GomeReina, Amelia Lopez-Ladron Garcia, Antonio Arrivi García-Ramos, Andrés Cervantes, C. Fernández Martos,
... Losa Gaspa (Consorci Sanitari CreuRoja, Barcelona); Jose Juan Ponce (Hospital Virgen de losLirios, Alicante); Carlos Bosch Roig (Hospital Universitario. Dr.Peset, Valencia); Pedro Valero Jimenez (Clínica Infanta Luisa, Sevilla); Antonio GalanBrotons (Hospital Sagunto, Sagunto); Santiago AlbiolRodriguez (Hospital Espiritu ...
Elsevier BV
Santiago Ponce Aix, Tudor‐Eliade Ciuleanu, Alejandro Navarro, Sophie Cousin, Laura Bonanno, Egbert F. Smit, Alberto Chiappori, M.E. Olmedo, Ildikó Horváth, Christian Grohé, Anna F. Farago, José Antonio López-Vilariño, Martín Cullell-Young, Antonio Nieto, Noelia Vasco, Javier Gómez, Carmen Kahatt, Ali Zeaiter, Enric Carcereny, Jaromı́r Roubec, Konstantinos Syrigos, Gregory Lo, I. Barneto, Anthony Pope, Amparo Martínez Sánchez, Joseph Kattan, Paul Zarogoulidis, Cornelius F. Waller, Helge Bischoff, Óscar Juan, Niels Reinmuth, Manuel Dómine, Luis Paz‐Ares,
Background Lurbinectedin is a synthetic marine-derived anticancer agent that acts as a selective inhibitor of oncogenic transcription. Lurbinectedin monotherapy (3·2 mg/m2 every 3 weeks) received accelerated approval from the US Food and Drug Administration on the basis of efficacy in patients with small-cell lung cancer (SCLC) who relapsed after first-line platinum-based chemotherapy. The ATLANTIS trial assessed the efficacy and safety of combination lurbinectedin and the anthracycline doxorubicin ...
Tópico(s): Cancer therapeutics and mechanisms
2022 - Elsevier BV | The Lancet Respiratory Medicine
Pedro Barrera-Baena, Minerva Rodríguez-García, Enrique Rodríguez-Rubio, Lucía González-Llorente, Alberto Ortíz, Carmine Zoccali, Francesco Locatelli, Jürgen Floege, Martine Cohen‐Solal, Aníbal Ferreira, Markus Ketteler, Gérard M. London, José Luis Górriz, J. Emilio Sánchez-Álvarez, Miguel Ángel Hevia-Suárez, J.M. Fernández Gómez, Beatriz Martín-Carro, Carlos Gómez‐Alonso, Cristina Alonso‐Montes, Jorge B. Cannata‐Andía, José Luis Fernández Martín, L Marosi, Allgemeines Krankenhaus, Bernhard Robl, Heinrich Kiss, Ulrich Neyer, Wilfried Jilly, Kramar, Dierik Verbeelen, Anne Wauters, R Cuvelier, C M De Mouscron, Max Dratwa, Chu Brugmann, Christian Tielemans, F. Dehout, Pierre Claus, A. Dhondt, B Jeren-Strujić, Marijana Gulin, Valentina Čorić-Martinović, Draško Pavlović, Jana Smržová, Pavlikova, Valkovsky, Zahradnik, Vladimı́r Teplan, Pavukova, Nemocnice Poliklinikou, Dialyzacni Stredisko, Moucka Nemocnice, Overlæge Kjeld Otte, Fredericia Sygehus, James Heaf, Overlæge Henning Danielsen, Viborg Sygehus, Mari Kolunen, L L Markku Asola, Philit Jean-Baptiste, Philippe Nicoud, François-Louis Maurice, Mohamed Brahim Bounab, Philippe Bertocchio, Guillaume Jean, Bony Chantal, Pierre Grimal, J. Gaultier, Alex Mouneimne, Brignon, Dupuy, Jean-Paul Jaulin, Pablo Ureña, Marc Pocheville, Valérie Masson, Marc Uzan, Dominique Besnier, M Labeeuw, Głowacki, Cattanéo, Bois Guillaume, D Didier, Bouchouareb, Petitjean Philippe, Dahmane Djamel, A N G Kim-Seng, Saveanu, Gérard M. London, Bouali Boussad, François-Pascal Wambergue, J.F. de Frémont, Michel, P Giraud, Jean-Paul Eche, Bernard S. López, Catherine Delcroix, Duchet, Ghandour Majdalani, Guy, Hadj, Marie-Paule Guillodo, Jochen Selbach, Arnold Röckel, B. Krumme, Bolley, M Grieger, Won-Ho Hahn, M. Daschner, Beate Iwig, Susanne Arendt, Dieter Berger, Bernd Wölbert, H Holzmann, Guenther Graf, Carsten Brockmann, W. J. Brech, A Mandelbaum, Wolfang Lauerwald, Johannes Bunia, Ulrich Lammer, Dieu Nguyet Au, Carsten Kurth, Schnierda, Stolz, Joachim Harlos, Steffen Berweck, Karl-August Brensing, Karl-August Brensing, Burkhard Kreft, Heinrich Jahnz, W. Kohnle, Wilfried Kamen, Sodemann, Peter Nachtigall, Jürgen Schäffer, Leimenstoll, K. Stenger, Wollschläger, Christine Langer, W Clasen, Christoph Röger, Klaus Burkhardt, J. P. Steinbach, Walter Schulz, Wolfgang Pommer, Michael Wilfling, Karla Schmaltz, Michael Eichhorn, B. L. Oser, E. Müller, Carola Striebing, H Schobel, Wolfgang Ludwig, Ulrich Frei, Helmut Peter Becker, Hans-Christoph Fischer, Maximilian Goller, Dieter Brückner, G Janning, Wolfgang Bagnewski, H. Preßler, Christoph C. Haufe, P. Grützmacher, Hans-Joachim Miska, Tomas Lenz, Olaf Frank Hoeft, Rolfdieter Krause, Kirsten de Groot, H. Armbruster, Peter Spellerberg, Wolfgang Stützer, Josef Nikolay, Rüdiger Schmidt, Johannes F.E. Mann, Rainer Roth, Johann-Borwin Lüth, Sybille Merscher, Hans-Jürgen Schmidt-Gürtler, Wolfgang Groß, Dehnert, Eva Roth, Jürgen Floege, Markus Ketteler, Stefan Heidenreich, Günter Bahlmann, Olaf Loke, Matthias Becker, Rolf Ebbinghaus, Matthias Weiß, Berhard Frye, F Matzkies, Katrin Gebauer, H-J Schurek, M. Heck, Helge Hohage, Ullrich Welling, M. Zeh, Schwietzer, Hermann Haller, Jochen Selbach, U. Metz-Kurschel, Roland Fulde, Christoph Ganzemüller, Jörg Radermacher, Joachim Materna, Oliver Hebgen, Bernhard Weber, Dieter Hummel, Scheuerle, Horst Kierdorf, Horst Kierdorf, Joachim Beige, Ralf Lorenz, Dimitrios Plakias, Stauroula Solomakou, Georgios Bristogiannis, Kleonikos Kalaitzidis, Dimitrios Kavvadias, Dimitrios Memmos, Antonis Papantoniou, Kyriaki Stamatelou, Ioannis Stefanidis, Konstantinos Siamopoulos, Csaba Rikker, Imre Kulcsár, B. Tichy, Sándor Ferenczi, Andrea Hering, Ottó Árkossy, Judit Nagy, Ascanio de Gregorio, Gianmaria Frattini, Antonio La Corte, Ugo Rotolo, Diego Brancaccio, Maurizio Gallieni, Fusaro, A Albertazzi, Livia Nazzaro, Francesco Randazzo, Francesco Locatelli, C Lodeserto, Angela D’Angelo, Giovanni M. Frascà, Fabio Malberti, Deni Aldo Procaccini, Cesare Dell, Goffredo Del Rosso, E Dialisi, Spotti Donatella, Giuseppe Bianchi, Marco Biagini, Filippo Aucella, Antonio Scarlatella, A Jeantet, E Dialisi, Marco Farina, Canulla Francesco, Maria Vittoria Cossu, Ssa Gina Meneghel, Mario Bonomini, Roberto Palla, Morosetti Massimo, Giancarlo Marinangeli, Rosella Estivi, Martin Giuliano, Antonio Santoro Md Poloclinico S Orsola-Malpighi, Renzo Scanziani, Conte Ferruccio, Giorgio Munatetto, Pastori Giordano, Giacomino Rossi, L Cagnoli, L Cagnoli, Massimo Morossetti, D Plutino, Alberto Galbiati, Loreto Gesualdo, M Querques, Giacomo Colussi, U Nefrologia, Andrea Macchi, Adalberto Tommasi, Eric F.H. van Bommel, Willem Jan W. Bos, Gaico H. Verseput, Louis Jean Vleming, C T Op De Hoek, Henk W. van Hamersvelt, Femke Hoekstra, H. A. H. Kaasjager, Magdalena Durlik, Miroslav Grzeszczyk, Andrzej Rydzewski, Dorota Śliwicka, Antoni Sydor, Tadeusz Gauda,
ABSTRACT Background Bone fragility fractures are associated with high morbidity and mortality. This study analysed the association between the current biochemical parameters of chronic kidney disease–mineral and bone disorders (CKD-MBD) and bone fragility fractures in the COSMOS (Current management Of Secondary hyperparathyroidism: a Multicentre Observational Study) project. Methods COSMOS is a 3-year, multicentre, open cohort, prospective, observational study carried out in 6797 haemodialysis patients ( ...
Oxford University Press